Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
7 hedge funds and large institutions have $61.3K invested in Rubius Therapeutics, Inc in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 37 closing their positions.
83% less funds holding
Funds holding: 42 → 7 (-35)
95% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 37
99% less capital invested
Capital invested by funds: $11.2M → $61.3K (-$11.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$15.3K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$803 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$6.55M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.13M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$838K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$293K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$229K |
RUBY Hedge Fund Activity: Q1 2023 in Review
7 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q1 2023, worth a combined $61.3K — down 99% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of RUBY and 2 opened new positions — a net loss of 35 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $15.3K. The largest seller was Flagship Pioneering, exiting entirely with an estimated $6.55M sold.
- 7 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q1 2023, down from 42 in Q4 2022.
- Funds reported $61.3K of Rubius Therapeutics, Inc stock for Q1 2023, down 99% quarter-over-quarter.
- 2 funds opened new Rubius Therapeutics, Inc positions in Q1 2023 and 37 closed out, a net change of -35 holders.
- The largest Rubius Therapeutics, Inc buyer in Q1 2023 was Baader Bank Aktiengesellschaft, an estimated $15.3K added.
- The largest Rubius Therapeutics, Inc seller in Q1 2023 was Flagship Pioneering, an estimated $6.55M sold.
Based on aggregated 13F filings for Q1 2023.